Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortization of Deferred ChargesAmortizatization of IntangiblesAmortizatization of IntangiblesCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Free Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesLong-Term Debt IssuancesLong-Term Debt RepaymentsNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsOther Working Capital ChangesOther Working Capital ChangesOther financing activitiesOther financing activitiesSales of Property, Plant and EquipmentSales of Property, Plant and EquipmentShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Heron Therapeutics (HRTX) Change in Receivables (2017 - 2026)

Heron Therapeutics filings provide 12 years of Change in Receivables readings, the most recent being -$5.9 million for Q1 2026.

  • On a quarterly basis, Change in Receivables fell 3964.83% to -$5.9 million in Q1 2026 year-over-year; TTM through Mar 2026 was $5.0 million, a 63.05% decrease, with the full-year FY2025 number at $10.7 million, down 42.88% from a year prior.
  • Change in Receivables hit -$5.9 million in Q1 2026 for Heron Therapeutics, down from $8.5 million in the prior quarter.
  • In the past five years, Change in Receivables ranged from a high of $25.2 million in Q2 2023 to a low of -$12.9 million in Q3 2023.
  • Median Change in Receivables over the past 5 years was $1.2 million (2025), compared with a mean of $2.8 million.
  • Biggest five-year swings in Change in Receivables: soared 3255.62% in 2023 and later plummeted 3964.83% in 2026.
  • Heron Therapeutics' Change in Receivables stood at $9.9 million in 2022, then crashed by 137.1% to -$3.7 million in 2023, then soared by 423.73% to $11.8 million in 2024, then fell by 27.88% to $8.5 million in 2025, then crashed by 169.02% to -$5.9 million in 2026.
  • The last three reported values for Change in Receivables were -$5.9 million (Q1 2026), $8.5 million (Q4 2025), and $1.1 million (Q3 2025) per Business Quant data.